Seres re­ceives $125M pay­ment from Nestlé; French biotech teas­es ear­ly-stage eye dis­ease da­ta

Seres Ther­a­peu­tics, a mi­cro­bio­me-fo­cused biotech, has been hand­ed a $125 mil­lion mile­stone pay­ment from Nestlé Heath Sci­ence re­lat­ed to the FDA ap­proval of its C. dif­fi­cile in­fec­tion treat­ment Vow­st.  

Seres and Nestlé came to­geth­er in 2021 to joint­ly com­mer­cial­ize the drug in the US and Cana­da. Fol­low­ing the com­mer­cial­iza­tion, both com­pa­nies are en­ti­tled to share equal­ly in the prof­its and any loss­es. Seres is al­so el­i­gi­ble to re­ceive pay­ments of up to $225 mil­lion for cer­tain sales mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.